← Leaderboards
Werner Tueckmantel
Psychogenics, Inc.
$944,482
Attributed
$944,482
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $495.6K · FY2007–10$500K$375K$250K$125K$0
'07
'08
'09
'10
Funding mix
By agency
NIH$944,482 · 2
By mechanism
R41$577,800 · 1
R43$366,682 · 1
Top collaborators
No co-investigators on record.
Most similar at Psychogenics, Inc.
Same institution · by research overlap
- Barbara J. Caldarone$943,262
- Paul McGonigle$1,350,000
- Mark A Varney$495,699
Others in their field
Top investigators on “Series”
- Lawrence Corey · Fred Hutchinson Cancer Center$445,660,381
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- David R. Weir · University Of Michigan At Ann Arbor$276,156,779
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$231,733,045
- Dennis R. Burton · Scripps Research Institute$199,946,411
- Joel A Lipkin · Four Points Technology, Llc$183,862,844
Research focus
SeriesAnalogIn VitroLeadCessation Of LifeProfessorIn VivoPublic Health Medicine (Field)AffinityAnimalsAdverse EffectsAnimal TestingApoptosisAreaAcetylationAngiogenesisBehaviorAdultBaseBinding (Molecular Function)BiologicalBlood - Brain Barrier AnatomyBrainAzetidines
Grant awards (6)
HDAC6-Selective Inhibitors for Pancreatic Cancer Treatment$147,605
R43 · FY2010 · CA · contact PI
HDAC6-Selective Inhibitors for Pancreatic Cancer Treatment$12,356
R43 · FY2009 · CA · contact PI
Nicotinic Ligands as Smoking Cessation Agents$288,900
R41 · FY2008 · DA · contact PI
HDAC6-Selective Inhibitors for Pancreatic Cancer Treatment$206,721
R43 · FY2008 · CA · contact PI
Nicotinic Ligands as Smoking Cessation Agents$223,806
R41 · FY2007 · DA · contact PI
Nicotinic Ligands as Smoking Cessation Agents$65,094
R41 · FY2007 · DA · contact PI